Account
Inquiry
Tirzepatide is a synthetic peptide analog with a sequence similar to semaglutide, incorporating a lysine side chain modified with PEG to improve water solubility. This modification enhances the functional properties of the polypeptide, making it suitable for various research applications. The primary physiological role of tirzepatide is as a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is currently under development for treating type 2 diabetes and has advanced to clinical stages.
Research indicates that tirzepatide may aid in weight loss for overweight individuals. Phase 3 clinical trials are ongoing to evaluate its efficacy in adults with obesity or weight-related health issues. The FDA has granted tirzepatide Fast Track designation to expedite its application process for obesity treatment. In the SURMOUNT-1 trial, participants experienced average weight reductions of 15% at 5mg, 19.5% at 10mg, and 20.9% at 15mg doses over 72 weeks.
Tirzepatide is administered once weekly and functions by mimicking the actions of GIP and GLP-1, hormones that promote insulin secretion. This dual agonist approach combines the benefits of two incretin-based therapies into a single molecule, offering a novel strategy for metabolic disorder research. It is provided as a white powder in sealed vials, ensuring stability and purity for laboratory use.
This product is intended for research purposes only and is not for personal use. Always handle with appropriate safety protocols in controlled environments.
